Efficacy, Satisfaction, and Safety of the Mesolipo® Protocol for the Treatment of Localized Adiposity (MESO-LA)
Eficácia,Satisfação e Segurança do Protocolo Mesolipo® no Tratamento da Gordura Localizada: um Estudo Randomizado
調査の概要
詳細な説明
Introduction: The Mesolipo® Protocol is a promising alternative for the treatment of localized adiposity, a condition that may negatively affect self-esteem and quality of life. Combining the principles of mesotherapy and intralipotherapy, this minimally invasive method aims to reduce localized fat effectively and safely through the administration of lipolytic substances.
Objectives: This study aims to evaluate the efficacy, patient satisfaction, and safety of the Mesolipo® Protocol for the treatment of localized adiposity.
Methods: This is a controlled clinical study involving 12 participants. Each participant will receive the Mesolipo® treatment on one side of the body and placebo on the contralateral side, allowing an intra-individual comparison of outcomes. Efficacy will be assessed using skinfold measurements, standardized photographs, and the Global Aesthetic Improvement Scale. Patient satisfaction will be evaluated using specific questionnaires, while safety will be monitored through detailed documentation of adverse events and complications. Descriptive and analytical statistical analyses will be performed. The study will comply with ethical research principles and will begin only after approval by the Research Ethics Committee. Participation will be conditional upon signing the Informed Consent Form.
Expected Results: The study is expected to provide relevant evidence regarding the feasibility, efficacy, and safety of the Mesolipo® Protocol for the treatment of localized adiposity. The findings may support the development of new therapeutic options and contribute to improving the quality of life of individuals affected by this condition.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、ブラジル、30493-240
- Instituto Antony Barbosa
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adults aged 18 years or older.
- Presence of localized adiposity suitable for treatment with the Mesolipo® protocol.
- Willingness and ability to provide written informed consent.
- Ability to comply with all study procedures and follow-up visits.
- Stable body weight for at least 3 months before enrollment.
- Agreement to maintain usual diet and physical activity habits throughout the study.
Exclusion Criteria:
- Pregnancy or breastfeeding.
- Known hypersensitivity to sodium deoxycholate or any study product component.
- Active infection or inflammatory skin disease at the treatment site.
- Previous aesthetic treatment in the target area within the period defined by the protocol.
- Severe systemic disease or any condition that, in the investigator's opinion, could interfere with study participation or outcome assessment.
- Participation in another clinical trial within the previous 30 days.
- Inability or unwillingness to comply with study procedures.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Mesolipo® Protocol
Participants will receive the Mesolipo® protocol on one side of the body for the treatment of localized adiposity.
The intervention consists of subcutaneous administration of the Mesolipo® formulation according to the standardized study protocol.
|
Mesolipo® is an injectable formulation containing sodium deoxycholate administered by subcutaneous injection for the treatment of localized adiposity.
The intervention is applied according to a standardized protocol regarding dose, injection technique, and treatment schedule.
|
|
アクティブコンパレータ：Active Comparator
Participants will receive the comparator intervention on the contralateral side of the body.
The comparator consists of the control formulation administered using the same injection technique and treatment schedule as the experimental intervention.
|
Pentoxifylline diluted in saline solution administered by subcutaneous injection using the same injection technique and treatment schedule as the experimental intervention.
This intervention serves as the active comparator.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment efficacy
時間枠：Baseline to Day 90
|
Assessed by the reduction in skinfold thickness measured using standardized skinfold calipers.
|
Baseline to Day 90
|
|
Treatment Safety
時間枠：Baseline to day 90
|
Safety will be assessed by the occurrence, frequency, and severity of treatment-related adverse events.
|
Baseline to day 90
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient satisfaction score assessed using a 5-point Likert satisfaction scale
時間枠：Day 90
|
Patient satisfaction will be assessed using a standardized 5-point Likert satisfaction scale at Day 90.
Scores range from 1 (very dissatisfied) to 5 (very satisfied).
The mean satisfaction score will be reported.
Higher scores indicate greater patient satisfaction.
|
Day 90
|
|
Global Aesthetic Improvement Scale (GAIS) score
時間枠：Baseline and Day 90
|
Aesthetic improvement will be assessed by a blinded evaluator using the Global Aesthetic Improvement Scale (GAIS).
GAIS is a 5-point scale ranging from -2 (much worse) to +2 (very much improved).
The mean GAIS score will be reported.
Higher scores indicate greater aesthetic improvement.
|
Baseline and Day 90
|
|
Photographic improvement score based on standardized clinical photographs
時間枠：Baseline and Day 90
|
Standardized clinical photographs obtained at Baseline and Day 90 will be independently evaluated by two blinded assessors.
Improvement will be rated using a predefined 5-point photographic improvement scale (0 = no improvement, 1 = slight improvement, 2 = moderate improvement, 3 = marked improvement, 4 = excellent improvement).
The mean photographic improvement score will be reported.
Higher scores indicate greater improvement in localized adiposity.
|
Baseline and Day 90
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 83014024.2.1001.5128
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。